Media About Us


  • 19 October 2016

    Chairman highlights 2016 industry highlights at OIS

    Chairman highlights 2016 industry highlights at OIS

    Healio

    The past year has seen a number of important approvals and promising study progress in both biotechnology and ophthalmic devices, Emmett T. Cunningham Jr., MD, PhD, MPH, told the more than 900 attendees at the Ophthalmology Innovation Summit in his “Chairman’s 2016 Year in Review.”

  • 19 October 2016

    Liquid biopsy open database created under Cancer Moonshot, as pharma joins the fray

    Liquid biopsy open database created under Cancer Moonshot, as pharma joins the fray

    Stacy Lawrence / Fierce Biotech

    Twenty stakeholders, including major biopharmas, diagnostic players and academic institutions, have committed to creating what they expect will be the largest liquid biopsy open database for cancer genomic profiling data. It’s part of the broader ongoing Cancer Moonshot effort led by U.S. Vice President Joe Biden.

  • 19 October 2016

    White House To Announce Big Push For Cancer Blood Tests

    White House To Announce Big Push For Cancer Blood Tests

    Matthew Herper / Forbes

    The White House, as part of the Cancer Moonshot effort being run by Vice President Joe Biden, is announcing a major push to develop blood tests that can detect and monitor cancer, that aims to unite makers of diagnostic tests, drugs, and other cancer-related products.

  • 18 October 2016

    Brian Dovey: Devices are less profitable investment targets than medicines

    Brian Dovey: Devices are less profitable investment targets than medicines

    Elena Krauzova / Forbes

    Does Russia have a chance to develop biotechnology, how innovation in biomedicine is born and how cure for cancer is developed? All this and many other things  was covered in Forbes interview with Brian Dovey, managing partner of venture fund Domain Associates, one of the founders and member of the Board of Directors of the Russian pharmaceutical company "NovaMedica".

  • 14 October 2016

    Biotech IPOs slow in Q3 despite improvement in general markets

    Biotech IPOs slow in Q3 despite improvement in general markets

    Peter Winter / BioWorld

    Biotech IPOs were sluggish in the third quarter, with only seven companies successfully completing their offerings on U.S. exchanges, raising a collective $396 million in the process, according to BioWorld analysis. That was 42 percent below the 12 biotech IPOs, raising $1.35 billion in the third quarter last year and 36 percent off the 11 companies completing their offerings in the second quarter this year, raising $564 million. 

  • 05 October 2016

    Raindrop Receives FDA Approval

    Raindrop Receives FDA Approval

    Maria Scott, MD / Ophthalmology Management

    This year, I celebrated my20th anniversary of laser vision correction. I first needed glasses for myopia when I was 12, but only wore them in emergencies because I didn't want to look “nerdy.” At age 16, I got gas permeable lenses, which I loved, and later, laser vision correction, because I hated wearing glasses.

  • 27 September 2016

    Two New Corneal Inlays Increase Options for Presbyopia

    Two New Corneal Inlays Increase Options for Presbyopia

    Roger F. Steinert, MD / MedScape

    Until recently, the go-to options for treating presbyopia were reading glasses, monovision with either a contact lens or laser vision correction, or multifocal intraocular lenses. Today we now have one more arrow in our quiver: the corneal inlay, which offers patients a safe, less invasive, and reversible alternative to laser vision correction and intraocular lenses.

  • 20 September 2016

    Allergan Buys Liver Drug Maker Tobira for Up to $1.7 Billion

    Allergan Buys Liver Drug Maker Tobira for Up to $1.7 Billion

    Doni Bloomfield / Bloomberg

    Allergan Plc agreed to buy Tobira Therapeutics Inc. for as much as $1.7 billion to gain a late-stage experimental drug to treat liver diseases, one of the most anticipated categories in biotechnology.

  • 20 September 2016

    Say what? Allergan just agreed to pay a 6X cash premium for Tobira and its troubled PhIII NASH drug

    John Carroll / ENDPOINTS

    A couple of months after a trial setback crushed Tobira’s share price, Allergan has swooped in to buy the company for $29.35 a share and up to $49.84 a share in contingent value rights if its late-stage NASH drug turns out to be a hit.

  • 20 September 2016

    Allergan to buy Tobira in push for NASH treatments

    Allergan to buy Tobira in push for NASH treatments

    Natalie Grover / Reuters

    Allergan Plc (AGN.N) said it would buy Tobira Therapeutics Inc (TBRA.O) in a deal worth up to $1.7 billion, about 19 times the company's current value, to get a leg up in the race to develop therapies for NASH, an incurable fatty liver disease.